Your search for Warfarin returned 102 results

Bristol-Myers Squibb and Pfizer announced that the reductions in stroke or systemic embolism, major bleeding and mortality demonstrated with Eliquis (apixaban) compared to warfarin (Coumadin; Bristol-Myers Squibb) in the Phase 3 ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation; these were results from a subanalysis from the study.

According to a new study published in JAMA, treatment with low molecular-weight heparin tinzaparin did not significantly reduce recurrent venous thromboembolism (VTE) or major bleeding and overall mortality compared to warfarin, but it did significantly reduce the risk of clinically relevant non-major bleeding in patients with active cancer.

The patients, a 71-year-old male and a 62 year-old-male, both on long-term warfarin therapy, presented to the emergency department with symptoms of COVID-19.

Pharmagen has launched Clotamin, a new vitamin K-free multivitamin formulation, in retail CVS stores.

Daiichi Sankyo announced positive results from the Phase 3 ENGAGE AF-TIMI 48 study comparing once-daily edoxaban with warfarin in patients with non-valvular atrial fibrillation (NVAF) at moderate-to-high risk of thromboembolic events.

Bristol-Myers Squibb and Pfizer announced results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial that assessed the effect of blood pressure control on outcomes as well as the treatment effect of Eliquis (apixaban) vs. warfarin to blood pressure control in patients with nonvalvular atrial fibrillation (NVAF).

The greatest risk reduction of stroke or systemic embolism was seen with dabigatran 150mg twice daily (odds ratio [OR] 0.65, 95% CI: 0.52-0.81), followed by apixaban 5mg twice daily (OR 0.79, 95% CI: 0.66-0.94).

The main outcomes and measures were intraocular bleeding events and associated risk ratio for NOACs, compared with warfarin.

CSL Behring announced results of a Phase 3b study that showed that a balanced, human 4-factor prothrombin complex concentrate (PCC) is as effective as the current standard of treatment in stopping bleeding in patients receiving vitamin K antagonist therapy (eg, warfarin).

Findings from a recent study suggests that clinical and genetic factors affecting warfarin dose requirements differ by race.